Michael J. Morris, MD, on Metastatic Prostate Cancer: Adding Abiraterone Acetate to Enzalutamide
2019 ASCO Annual MeetingMichael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, discusses the phase III findings from the Alliance A031201 trial, which showed that adding abiraterone acetate to enzalutamide did not improve survival in men with metastatic castration-resistant prostate cancer (Abstract 5008).
Related Videos
Daniel P. Petrylak, MD, on Urothelial Cancer: Enfortumab Vedotin Monotherapy for Locally Advanced or Metastatic Disease
Daniel P. Petrylak, MD, of Yale School of Medicine, discusses study results on enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously ...
Sagar Lonial, MD, on Smoldering Multiple Myeloma: Delaying Disease Progression With an Immunomodulatory Agent
Sagar Lonial, MD, of Winship Cancer Institute of Emory University, discusses the potentially practice-changing phase III findings showing that lenalidomide substantially delayed pr...
François-Xavier Mahon, MD, PhD, on Chronic-Phase Chronic Myeloid Leukemia: Treatment-Free Remission After Second-Line Treatment
François-Xavier Mahon, MD, PhD, of the Université Bordeaux and Institut Bergonie, discusses results of the ENESTop study, which demonstrated the long-term durability and safe...
Miriam Knoll, MD, and Zachery Reichert, MD, PhD, on Prostate Cancer: Focal Radiation for Oligometastatic Castration-Resistant Disease
Miriam Knoll, MD, of Hackensack University Medical Center, and Zachery Reichert, MD, PhD, of the University of Michigan, discuss the FORCE trial, which exami...
Richard Pazdur, MD, on the Launch of Project Facilitate
Richard Pazdur, MD, Director of the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence and Acting Director of the Office of Hematology and Oncology Products in t...
